All In Biotech

BLA 761181 · Regeneron Pharmaceuticals

Evkeeza

Evinacumab-Dgnb · Injection

NovelBreakthrough therapyPriority reviewOrphan

CDER novel approval, Feb 11, 2021: To treat homozygous familial hypercholesterolemia

Last checked: Nov 20, 2026Latest source record: Sep 25, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Feb 11, 2021

Approved uses

3

Original approval plus efficacy supplements

Registered trials

12

4 Phase 3, 1 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. FDA's summary: To treat homozygous familial hypercholesterolemia

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 25, 2025 Supplement 2 · Efficacy · priority review Breakthrough therapyOrphanLetterLabel
  • Mar 21, 2023 Supplement 1 · Efficacy · priority review OrphanLabelLetter
  • Feb 11, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
2 products under this application
  • EVKEEZA · EVINACUMAB-DGNB 345MG/2.3ML · SOLUTION, INJECTION · Prescription
  • EVKEEZA · EVINACUMAB-DGNB 1200MG/8ML · SOLUTION, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Evinacumab" as an intervention, any sponsor and status, largest first.

All 12 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Evkeeza (Evinacumab-Dgnb)

2024 spending

$10.8M

Beneficiaries

27

245 claims

Per beneficiary

$400,140

$5,383.69 per unit

View as table
YearSpending
2020$0
2021$777,909
2022$3,474,160
2023$6,739,753
2024$10,803,789

Part B: Evkeeza (Evinacumab-Dgnb) · HCPCS J1305

2024 spending

$21.8M

Beneficiaries

63

541 claims

Per beneficiary

$346,737

2024 ASP limit $181.81 per unit

View as table
YearSpending
2020$0
2021$400,316
2022$4,166,459
2023$10,904,082
2024$21,844,436

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 24 on PubMed

Sponsor: Regeneron

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.